Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era

Yu Chung Huang, Chun Yu Liu, Hsueh Ju Lu, Han Tsung Liu, Man Hsin Hung, Ying Chung Hong, Liang Tsai Hsiao, Jyh Pyng Gau, Jin Hwang Liu, Hui Chi Hsu, Tzeon Jye Chiou, Po Min Chen, Cheng Hwai Tzeng, Yuan Bin Yu

研究成果: 雜誌貢獻回顧型文獻同行評審

18 引文 斯高帕斯(Scopus)


Several revisions of International Prognostic Index (IPI) have been proposed for patients with diffuse large B-cell lymphoma (DLBCL) after the introduction of rituximab. Expanding evidence suggests that baseline absolute lymphocyte count (ALC) is also an independent factor for outcome prediction. We investigated the optimal prognostic model for these patients in the rituximab era. The study enrolled 274 consecutive patients with DLBCL receiving first-line cyclophosphamide, doxorubicin, vincristine, and prednisone based chemotherapy with rituximab between 2003 and 2009. Five factors within IPI and ALC were entered for Cox regression analysis. Overall survival (OS) and progression-free survival were calculated for different risk groups of models. Efficacy of models was compared by the value of Akaike information criterion (AIC). Revised IPI (R-IPI) and ALC/R-IPI, but not IPI, were informative to discriminate between different risk groups. In multivariate analysis for individual factors of the prognostic models, performance status >1 [odds ratio (OR) 3.59], Ann Arbor stage III or IV (OR 2.24), and ALC <1 × 109/L (OR, 2.75) remained significant. Another modified score based on the three factors divided patients into four risk groups and the 3-year OS rate was 93, 77, 39, and 13 %, respectively. By comparing AIC values in the Cox proportional hazards model, the modified three-factor model was the superior prognostic model followed by established ALC/R-IPI, R-IPI, and standard IPI. In conclusion, the addition of the novel factor, ALC, interacts with other established factors in outcome prediction for DLBCL. Development of a new score is needed for a better risk stratification in the rituximab era and would be helpful in the design of future clinical trials. The proposed three-factor model should be validated in large-scale studies.

頁(從 - 到)1513-1520
期刊Annals of Hematology
出版狀態已發佈 - 11月 2013

ASJC Scopus subject areas

  • 血液學


深入研究「Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era」主題。共同形成了獨特的指紋。